BPH Market & Aquablation Therapy - Benign Prostatic Hyperplasia (BPH) affects approximately 40 million men in the U S [21] - The U S BPH surgical market represents a ~$20 billion opportunity [27] - Approximately 70% of prostates treated with Aquablation in the U S are less than 100ml in size [41] - Aquablation therapy provides effective, safe, and durable outcomes independent of prostate size, shape, and surgeon experience [36] Financial Performance & Guidance - Total revenue increased by 72% year-over-year to $24 4 million in Q1 2023 [51] - U S Aquabeam install base increased by 106% year-over-year to 192 systems in Q1 2023 [51] - U S handpieces sold increased by 139% year-over-year in Q1 2023 [51] - The company projects total revenue of $128 0 million for 2023, representing approximately 71% year-over-year growth [53, 54] - The company anticipates a gross margin of 54% for 2023 [54] Commercial Strategy & Expansion - The company is targeting 860 high-volume hospitals in the U S with an annual resective volume of ≥100 procedures [62] - 17 Strategic IDNs account for ~29% of BPH hospitals and ~26% of high-volume centers [70] - 65% of high volume hospitals are within a 100-mile radius of Robotic Sales Representatives [73]

Investor Event © 2024 PROCEPT BioRobotics Corporation. All Rights Reserved. Safe Harbor Statement This presentation and accompanying oral presentation contain "forw ard-looking statements" w ithin the meaning of the Private Securities Litigation Reform Act of 1995, including the ex pected financial results of PROCEPT BioRobotics Corporation (the "Company"). W ords such as "anticipates," "believes," "ex pects," "intends," "projects," "anticipates," and "f uture" or similar ex pressions are intended to identi ...

Group 1 - The company, PROCEPT BioRobotics, is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at four investor conferences in May and June 2025, including the Bank of America Health Care Conference and the Jefferies Global Healthcare Conference [1][2] - PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] Group 2 - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), impacting approximately 40 million men in the U.S. [3] - The company has developed a significant body of clinical evidence, with over 150 peer-reviewed publications supporting the benefits of Aquablation therapy [3] - The company aims to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions [3]

Core Insights - PROCEPT BioRobotics Corporation is showcasing its leadership in BPH treatment through extensive scientific presentations and workshops at the 2025 AUA Annual Meeting [1][2] - Aquablation therapy is highlighted as a transformative solution for BPH, offering durable symptom relief with minimal side effects [2][15] Company Overview - PROCEPT BioRobotics focuses on advancing urologic care through innovative surgical robotics, specifically the AQUABEAM and HYDROS Robotic Systems [15] - The company aims to revolutionize BPH treatment globally, impacting approximately 40 million men in the United States [15] Clinical Data and Presentations - Clinical presentations at AUA will emphasize long-term outcomes, safety, and durability of Aquablation therapy [2] - A series of thought leader presentations will take place, featuring insights from various experts on the role of Aquablation in modern urology [3][4][5][6][7] Event Activities - PROCEPT's booth will host hands-on demonstrations of the HYDROS Robotic System, allowing urologists to explore the technology and discuss clinical experiences [8] - The AUA Scientific Program will feature multiple podium and poster presentations focused on Aquablation therapy [9][10] Technology and Innovation - Aquablation therapy is described as the first ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH, allowing for personalized treatment planning [13] - The technology enables precise and controlled removal of prostate tissue while preserving critical anatomical functions [13]

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive Vice President & Chief Commercial Officer Kevin Waters - Executive Vice President & Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America Securities Patrick Wood - Morgan Stanley Ri ...